Table 1.

Recipient and donor clinical data

Product	Age R (yrs)	Age D (yrs)	Source	MUD/Sib	Engraftment (day)	TNC/kg bw (108/kg)	CMV serology (D)	CMV serology (R)	EBV serology (D)	EBV serology (R)	Diagnosis	Infectious complications within 1 yr after HSCT	ATG Yes/no	Other clinical information
1	66	25	PB	MUD	25	5·8	Pos	Pos	Neg	Posb	ALL Ph+	CMV, HSV‐2 HSV‐1	Y	Relapse
2	47	41	BM	MUD	19	2·7	Pos	Pos	Pos	Pos	AML		Y
3	48	46	PB	Sib	11	23·2	Neg	Posa	Pos	Pos	MDS	CMV, Staph + E‐coli sepsis, HSV‐1	N	GVHD grade III, Deceased
4	28	24	PB	MUD	15	16·7	Pos	Pos	Pos	Pos	Pre‐B ALL		Y	Chronic GVHD grade I
5	1	29	BM	MUD	20	11·4	Neg	Neg	Pos	Negb	CGD (X‐linked)	EBV, CMV	Y
6	16	28	BM	MUD	14	3·9	Neg	Posa	Pos	Pos	Pre‐B ALL	CMV, Oral Candidiasis	Y
7	53	26	PB	MUD	14	8	Neg	Posa	Pos	Pos	MDS		Y
8	35	28	PB	MUD	22	12	Neg	Posa	Pos	Pos	Pre‐B ALL	CMV, HSV‐1, EBV	Y	GVHD grade II, CMV CTL
9	68	38	PB	MUD	18	11·3	Neg	Posa	Pos	Pos	MDS	VZV, CMV	Y	Relapse
10	10	7	BM	Sib	17	3·9	Pos	Pos	Neg	Posb	Pre‐B ALL	VZV	N	Chronic GVHD grade II
11	67	33	PB	MUD	32	14·2	Pos	Pos	Pos	Pos	AML		Y	Pneumonia, Deceased
12	66	29	PB	MUD	16	7·9	Neg	Neg	Pos	Pos	AML	VZV	Y
13	9	27	PB	MUD	15	25·4	Pos	Pos	Pos	Pos	AML Ph+		Y
15	44	43	PB	MUD	18	4·5	Neg	Posa	Pos	Pos	AML	CMV	N
16	49	34	PB	MUD	17	7	Neg	Posa	Pos	Negb	Myeloma	EBV, CMV, Salmonella+Staph abscess, sepsis.	Y	Relapse
17	46	34	PB	MUD	31	14·3	Pos	Pos	Pos	Pos	AML		N	Relapse, Deceased
18	48	24	PB	MUD	19	12·3	Pos	Pos	Neg	Neg	AML	CMV, VZV	Y	Relapse
19	49	46	PB	Sib	18	4·1	Pos	Pos	Pos	Pos	AML/myelofibrosis		N	Relapse, Deceased
20	62	26	PB	MUD	16	6·8	Pos	Pos	Pos	Pos	MDS		Y
21	68	27	PB	MUD	13	13·2	Neg	Neg	Pos	Pos	AML		Y
22	15	19	BM	Sib	19	3·3	Neg	Neg	Neg	Neg	T‐cell lymphoma	VZV, Oral Candidiasis, Corona virus pneumonia	N	GVHD grade II
	Median 48 (1–68)	Median 28 (7–46)	16 PB/5 BM	17 MUD/4 Sib	Median 18 (11–32)	Median 8 (2·7–25·4)	10 P/11 N	17 P/4 N	17 P/4 N	16 P/5 N			15/6 Y/N

D, Donor, R: recipient, PB, peripheral blood stem cells, BM, bone marrow, MUD, matched unrelated donor, Sib, sibling, TNC, Total nucleated cells, ALL, acute lymphocytic leukaemia, AML, acute myeloid leukaemia, MDS, myelodysplastic syndrome, CGD, chronic granulomatous disease, CMV, Cytomegalovirus, HSV, Herpes simplex virus 1 and 2, EBV, Epstein–Barr virus, VZV, Varicella‐zoster virus, ATG, antithymocyte immuno‐globuline, GVHD, Graft versus host disease.

^aCMV mismatch.

^bEBV mismatch.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.